Aimmune Therapeutics, Inc. (AIMT:NASDAQ) Investor Relations Material

Overview

Aimmune Therapeutics is a biopharmaceutical company focused on developing cures for food allergies. The company's Characterized Oral Desensitization (CODIT) approach is designed to protect patients from life-threatening allergic reactions caused by accidental food allergen exposure. Aimmune currently has one FDA-approved treatment for peanut allergy, and is also developing therapies for other food allergies. The company's goal is to become the global leader in food allergy treatments and improve the lives of people with food allergies.

Frequently Asked Questions

What is Aimmune Therapeutics, Inc.'s ticker?

Aimmune Therapeutics, Inc.'s ticker is AIMT

What exchange is Aimmune Therapeutics, Inc. traded on?

The company's shares trade on the NASDAQ stock exchange

Where are Aimmune Therapeutics, Inc.'s headquarters?

They are based in Brisbane, California

How many employees does Aimmune Therapeutics, Inc. have?

There are 501-1000 employees working at Aimmune Therapeutics, Inc.

What is Aimmune Therapeutics, Inc.'s website?

It is https://www.aimmune.com/

What type of sector is Aimmune Therapeutics, Inc.?

Aimmune Therapeutics, Inc. is in the Healthcare sector

What type of industry is Aimmune Therapeutics, Inc.?

Aimmune Therapeutics, Inc. is in the Biotechnology industry

Who are Aimmune Therapeutics, Inc.'s peers and competitors?

The following five companies are Aimmune Therapeutics, Inc.'s industry peers:

- Interpace Biosciences, Inc.

- ImmunoGen

- EverGen Infrastructure

- Novelion Therapeutics Inc.

- Beam Therapeutics